Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Phase 3 Terminated 69 enrolled Windtree Therapeutics

RandomizedParallel-groupOpen-labelTreatment

Summary

OBJECTIVES: Evaluate the safety and efficacy of lucinactant administered by bronchoalveolar lavage (BAL) in the treatment of meconium aspiration syndrome (MAS) in newborn infants.

Timeline

Start: 2000-03
Primary completion: 2002-11
Completion: 2004-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lucinactant	Peptide	10 mg/ml	Other

Phase III Randomized Study of Lucinactant in Full Term Newborn Infants With Meconium Aspiration Syndrome

Summary

Timeline

Drugs

Indications